What does PHARM-INTER do?

PHARM-INTER is registered with the CBE as active in: Groothandel in farmaceutische producten. Private Limited, started on 5 September 1984, 1 establishment.

What is the address of PHARM-INTER?

The registered office of PHARM-INTER is located at Kasteellaan 108, 1081 Koekelberg.

Is PHARM-INTER still active?

Yes. According to the CBE (29 October 2026) PHARM-INTER is active, legal situation “Normale toestand”, started on 5 September 1984.

Is PHARM-INTER registered on Peppol?

Yes, PHARM-INTER is registered on the Peppol network with ID 0208:0427154841.

What is the enterprise number of PHARM-INTER?

The enterprise number of PHARM-INTER is BE0427154841.

When was PHARM-INTER founded?

PHARM-INTER was founded on 5 September 1984.

Who are the directors of PHARM-INTER?

According to the 2025 annual accounts, the directors of PHARM-INTER are: Jesus DIEZ.

Is PHARM-INTER a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 September 1984; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARM-INTER make in 2025?

PHARM-INTER posted a profit after taxes of € 307,007 in financial year 2025.

What is the revenue of PHARM-INTER?

As a small company, PHARM-INTER is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,175,081.

How much does an employee at PHARM-INTER earn?

The average wage cost per full-time employee at PHARM-INTER was € 87,100 in 2025: staff costs of € 296,304 for 3.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARM-INTER have?

According to the 2025 annual accounts, PHARM-INTER has 3.4 full-time equivalents (FTE).

PHARM-INTER (Private Limited) - Koekelberg - BE0427154841

Dossier PHARM-INTER, printed on 29 October 2026 from databakkes.be/en/0427154841/pharm-inter. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARM-INTER from Koekelberg, company number BE0427154841, closed financial year 2025 with a result of € 307,007 after tax. For that financial year PHARM-INTER recorded a gross margin of € 1.2 million and equity of € 933,135. Compared with financial year 2024, the result moved from € 344,710 to € 307,007. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 21, 2026.

What it is worth Growing

€ 933,135

▲ 9% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 307,007

▼ 11% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 3.2 million

▲ 131% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 230,000 paid out

75 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

3.4

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 296,304

▲ 10% vs 2024

€ 87,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 20,680

▼ 25% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 251,526

▲ 13% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 6.2 million

▼ 1% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 79,057

▲ 13% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 745,800 Gross margin 2022: € 745,800 First fiscal year in the series	€ 959,385 Gross margin 2023: € 959,385 ▲ 29% vs 2022 (€ 745,800) Favourable step	€ 874,621 Gross margin 2024: € 874,621 ▼ 9% vs 2023 (€ 959,385) Unfavourable step	€ 1,175,081 Gross margin 2025: € 1,175,081 ▲ 34% vs 2024 (€ 874,621) Favourable step	▲ 34%
Profit after taxes	€ 280,725 Profit after taxes 2022: € 280,725 First fiscal year in the series	€ 442,169 Profit after taxes 2023: € 442,169 ▲ 58% vs 2022 (€ 280,725) Favourable step	€ 344,710 Profit after taxes 2024: € 344,710 ▼ 22% vs 2023 (€ 442,169) Unfavourable step	€ 307,007 Profit after taxes 2025: € 307,007 ▼ 11% vs 2024 (€ 344,710) Unfavourable step	▼ 11%
Equity	€ 769,249 Equity 2022: € 769,249 First fiscal year in the series	€ 861,418 Equity 2023: € 861,418 ▲ 12% vs 2022 (€ 769,249) Favourable step	€ 856,128 Equity 2024: € 856,128 ▼ 1% vs 2023 (€ 861,418) Unfavourable step	€ 933,135 Equity 2025: € 933,135 ▲ 9% vs 2024 (€ 856,128) Favourable step	▲ 9%
Total debts	€ 4,628,754 Total debts 2022: € 4,628,754 First fiscal year in the series	€ 6,648,049 Total debts 2023: € 6,648,049 ▲ 44% vs 2022 (€ 4,628,754) Unfavourable step	€ 6,935,345 Total debts 2024: € 6,935,345 ▲ 4% vs 2023 (€ 6,648,049) Unfavourable step	€ 6,773,422 Total debts 2025: € 6,773,422 ▼ 2% vs 2024 (€ 6,935,345) Favourable step	▼ 2%
Cash	€ 952,057 Cash 2022: € 952,057 First fiscal year in the series	€ 1,925,596 Cash 2023: € 1,925,596 ▲ 102% vs 2022 (€ 952,057) Favourable step	€ 1,397,237 Cash 2024: € 1,397,237 ▼ 27% vs 2023 (€ 1,925,596) Unfavourable step	€ 3,233,574 Cash 2025: € 3,233,574 ▲ 131% vs 2024 (€ 1,397,237) Favourable step	▲ 131%
Land & buildings	€ 47,298 Land & buildings 2022: € 47,298 First fiscal year in the series	€ 41,686 Land & buildings 2023: € 41,686 ▼ 12% vs 2022 (€ 47,298) Unchanged	€ 36,074 Land & buildings 2024: € 36,074 ▼ 13% vs 2023 (€ 41,686) Unchanged	€ 30,463 Land & buildings 2025: € 30,463 ▼ 16% vs 2024 (€ 36,074) Unchanged	▼ 16%
Retained profit	€ 419,249 Retained profit 2022: € 419,249 First fiscal year in the series	€ 511,418 Retained profit 2023: € 511,418 ▲ 22% vs 2022 (€ 419,249) Favourable step	€ 506,128 Retained profit 2024: € 506,128 ▼ 1% vs 2023 (€ 511,418) Unfavourable step	€ 583,135 Retained profit 2025: € 583,135 ▲ 15% vs 2024 (€ 506,128) Favourable step	▲ 15%
Dividend	€ 130,000 Dividend 2022: € 130,000 First fiscal year in the series	€ 350,000 Dividend 2023: € 350,000 ▲ 169% vs 2022 (€ 130,000) Unchanged	€ 350,000 Dividend 2024: € 350,000 Unchanged (€ 350,000) Unchanged	€ 230,000 Dividend 2025: € 230,000 ▼ 34% vs 2024 (€ 350,000) Unchanged	▼ 34%
Bank debt	€ 29,588 Bank debt 2022: € 29,588 First fiscal year in the series	€ 55,837 Bank debt 2023: € 55,837 ▲ 89% vs 2022 (€ 29,588) Unfavourable step	€ 222,806 Bank debt 2024: € 222,806 ▲ 299% vs 2023 (€ 55,837) Unfavourable step	€ 251,526 Bank debt 2025: € 251,526 ▲ 13% vs 2024 (€ 222,806) Unfavourable step	▲ 13%
Balance sheet total	€ 5,398,003 Balance sheet total 2022: € 5,398,003 First fiscal year in the series	€ 7,509,467 Balance sheet total 2023: € 7,509,467 ▲ 39% vs 2022 (€ 5,398,003) Unchanged	€ 7,791,473 Balance sheet total 2024: € 7,791,473 ▲ 4% vs 2023 (€ 7,509,467) Unchanged	€ 7,706,557 Balance sheet total 2025: € 7,706,557 ▼ 1% vs 2024 (€ 7,791,473) Unchanged	▼ 1%
Employees (FTE)	3.4 Employees (FTE) 2022: 3.4 First fiscal year in the series	3.4 Employees (FTE) 2023: 3.4 Unchanged (3.4) Unchanged	3.4 Employees (FTE) 2024: 3.4 Unchanged (3.4) Unchanged	3.4 Employees (FTE) 2025: 3.4 Unchanged (3.4) Unchanged

Key figures of PHARM-INTER, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARM-INTER?

What happened at PHARM-INTER in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 21, 2026 New annual accounts for financial year 2025: profit of € 307,007 (▼ 11% vs 2024). Source: NBB ↗
Sep 4, 1986 New establishment in Koekelberg. KBO
Sep 5, 1984 Start of the company according to the CBE. KBO

In short

From € 280,725 profit in 2022 to € 307,007 profit in 2025.

Paid € 544,082 in corporate taxes since 2022.

Best year ever: 2023, with € 442,169 profit.

On average € 345,600 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Jesus DIEZ

PHARM-INTER

Behind PHARM-INTER is Jesus DIEZ.

Directors

According to the 2025 annual accounts

Jesus DIEZ

Administrator-manager

Establishments

Establishment units

Physical locations of this company

Registered office

Kasteellaan 108

1081 Koekelberg

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

ATHENA MANAGEMENT COMPANY

€ -12,919 gross margin · 2024

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0427.154.841

VAT number

BE 0427.154.841

Registered office

Kasteellaan 108, 1081 Koekelberg

Names & denominations

PHARM-INTER

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

5 September 1984

Peppol

Active · Active since 15 Dec 2025

Activities · NACE

Groothandel in farmaceutische producten

Groothandel in farmaceutische en medische artikelen

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARM-INTER

Financials

What happened to PHARM-INTER?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions